JAC Advance Access originally published online on March 31, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 875-877
© 2004 The British Society for Antimicrobial Chemotherapy
Moxifloxacin penetration into human gastrointestinal tissues
1 Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg; 2 Institute of Hygiene, University of Heidelberg, Im Neuenheimer Feld 324, D-69120 Heidelberg; 3 Pharmacy Department, University of Heidelberg, Im Neuenheimer Feld 670, D-69120 Heidelberg, Germany
Received 13 November 2003; returned 16 January 2004; revised 31 January 2004; accepted 6 February 2004
Objective: Moxifloxacin is a recently developed fourth-generation methoxyquinolone with a broad spectrum of activity against both Gram-positive and Gram-negative aerobic bacteria and anaerobes. The aim of the present study was to assess the penetration of moxifloxacin into gastrointestinal (GI) mucosal tissues to evaluate its potential role as an antimicrobial drug in bacterial infections of the GI tract.
Patients and methods: Twenty-eight patients undergoing GI-tract surgery received 400 mg of moxifloxacin twice pre-operatively [eight patients orally (po) and 20 patients intravenously (iv)], of whom 22 completed the study. Mucosal tissues (three stomach, three small bowel and 16 colon) and serum samples were collected and moxifloxacin concentrations were measured by HPLC.
Results: The highest tissue concentrations were detected in the mucosa of the stomach (10.9 ± 5.1 mg/kg), followed by colon mucosa (7.8 ± 7.1 mg/kg after iv; 6.6 ± 3.6 mg/kg after po) and small bowel mucosa (5.4 ± 0.5 mg/kg). The tissue-to-serum ratio of moxifloxacin was 2.0 ± 1.6 in the small bowel mucosa, 5.8 ± 3.4 and 6.8 ± 3.9 in the colon mucosa after po and iv administration, respectively, and 9.7 ± 5.7 in the stomach mucosa.
Conclusion: Moxifloxacin penetrates into and accumulates in the mucosa of the stomach, small bowel and colon. The clinical applicability of moxifloxacin administration for bacterial GI-tract infections should be investigated in controlled trials.
Keywords: methoxyquinolone, bacterial infection, tissue concentrations
* Corresponding author. Tel: +49-6221-564860; Fax: +49-6221-566903; E-mail: joerg_kleeff{at}med.uni-heidelberg.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Ober, T. Hoppe-Tichy, J. Koninger, O. Schunter, H.-G. Sonntag, M. A. Weigand, J. Encke, C. Gutt, and S. Swoboda Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections J. Antimicrob. Chemother., November 1, 2009; 64(5): 1091 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Stass, A. D. Rink, H. Delesen, D. Kubitza, and K.-H. Vestweber Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis J. Antimicrob. Chemother., September 1, 2006; 58(3): 693 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. C. Goldstein, D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|